BCTXF News and Press, BriaCell Therapeutics From 02/11/19

Multiple breakthroughs in the field of onco-immunology are expected over the next 20 years BriaCell Therapeutics Corp. is a frontrunner in this area, as it has already established proof of concept for its Bria-IMT solution for advanced breast cancer patients The company is also developi...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is currently developing immunotherapy solutions demonstrated to be highly effective and well tolerated by patients. The market share for immunotherapy treatments for breast cancer as well as ...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is advancing the development of a cost-saving solution for cancer patients. An article discussing the company reads, “BriaCell’s development of Bria-OTS, a personalized immunoth...

Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites New formulation to accommodate higher patient volumes at reduced per-dose costs Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast c...

The market share of immunotherapy treatments for breast cancer and other malignancies is expected to increase exponentially by 2024 The incidence of breast cancer is set to grow by 50 percent in the next decade BriaCell Therapeutics Corp. has already established the effectiveness of its...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently reported the impending clinical use of a novel frozen formulation of the company’s lead cancer drug candidate, Bria-IMT. The new, easy-to-use formulation can be transported mo...